Should I buy or sell TRACON Pharmaceuticals stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TRACON Pharmaceuticals in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" TCON shares. View TCON analyst ratings or view top-rated stocks .

What is TRACON Pharmaceuticals' stock price target for 2024?

3 analysts have issued 12-month price targets for TRACON Pharmaceuticals' shares. Their TCON share price targets range from $60.00 to $60.00. On average, they expect the company's share price to reach $60.00 in the next year. This suggests a possible upside of 2,743.6% from the stock's current price. View analysts price targets for TCON or view top-rated stocks among Wall Street analysts .

How have TCON shares performed in 2024?

TRACON Pharmaceuticals' stock was trading at $3.5020 at the start of the year. Since then, TCON shares have decreased by 39.7% and is now trading at $2.11. View the best growth stocks for 2024 here .

Are investors shorting TRACON Pharmaceuticals?

TRACON Pharmaceuticals saw a drop in short interest during the month of March. As of March 31st, there was short interest totaling 744,900 shares, a drop of 60.8% from the March 15th total of 1,900,000 shares. Based on an average daily trading volume, of 3,400,000 shares, the short-interest ratio is presently 0.2 days. View TRACON Pharmaceuticals' Short Interest .

When is TRACON Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our TCON earnings forecast .

How were TRACON Pharmaceuticals' earnings last quarter?

TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) announced its quarterly earnings data on Tuesday, March, 5th. The biopharmaceutical company reported $0.20 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.60) by $0.80. The biopharmaceutical company had revenue of $3.41 million for the quarter, compared to analysts' expectations of $3 million.

When did TRACON Pharmaceuticals' stock split?

TRACON Pharmaceuticals's stock reverse split on the morning of Wednesday, April 10th 2024. The 1-20 reverse split was announced on Wednesday, April 10th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, April 10th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of TRACON Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other TRACON Pharmaceuticals investors own include NVIDIA (NVDA) , OPKO Health (OPK) , SCYNEXIS (SCYX) , Sorrento Therapeutics (SRNE) , Verastem (VSTM) , Inovio Pharmaceuticals (INO) , T2 Biosystems (TTOO) , AVEO Pharmaceuticals (AVEO) , Corbus Pharmaceuticals (CRBP) and Onconova Therapeutics (ONTX) .

When did TRACON Pharmaceuticals IPO?

TRACON Pharmaceuticals (TCON) raised $47 million in an IPO on Friday, January 30th 2015. The company issued 3,600,000 shares at $12.00-$14.00 per share. Wells Fargo Securities and Stifel served as the underwriters for the IPO and Needham & Company and Oppenheimer were co-managers.

How do I buy shares of TRACON Pharmaceuticals?

Shares of TCON stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:TCON

TRACON Pharmaceuticals (TCON) Stock Price, News & Analysis

→ SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad)

Free TCON Stock Alerts

$2.11

-0.18 (-7.86%)

(As of 04/18/2024 ET)

Compare

Today's Range: $2.06
▼
$2.34
50-Day Range: $1.71
▼
$12.62
52-Week Range: $1.59
▼
$36.90

Volume: 351,085 shs
Average Volume: 199,291 shs
Market Capitalization: $4.81 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $60.00

Get TRACON Pharmaceuticals alerts:

TRACON Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.67 Rating Score
Upside/Downside: 2,743.6% Upside
$60.00 Price Target
Short Interest: Healthy
32.67% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($4.00) to ($5.40) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.48 out of 5 stars

3.3

Analyst's Opinion

Consensus Rating
TRACON Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.
Amount of Analyst Coverage
TRACON Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
32.67% of the outstanding shares of TRACON Pharmaceuticals have been sold short.
Short Interest Ratio / Days to Cover
TRACON Pharmaceuticals has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in TRACON Pharmaceuticals has recently decreased by 60.79%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
TRACON Pharmaceuticals does not currently pay a dividend.
Dividend Growth
TRACON Pharmaceuticals does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for TCON.

2.7

News and Social Media Coverage

News Sentiment
TRACON Pharmaceuticals has a news sentiment score of 0.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.50 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for TRACON Pharmaceuticals this week, compared to 1 article on an average week.
Search Interest
29 people have searched for TCON on MarketBeat in the last 30 days. This is an increase of 71% compared to the previous 30 days.
MarketBeat Follows
Only 7 people have added TRACON Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -65% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, TRACON Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 5.27% of the stock of TRACON Pharmaceuticals is held by insiders.
Percentage Held by Institutions
Only 11.61% of the stock of TRACON Pharmaceuticals is held by institutions.

0.0

Earnings and Valuation

Earnings Growth
Earnings for TRACON Pharmaceuticals are expected to decrease in the coming year, from ($4.00) to ($5.40) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of TRACON Pharmaceuticals is -0.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of TRACON Pharmaceuticals is -0.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

Ad Crypto 101 Media

SHOCKING Crypto Leak…

A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

Claim your free seat by clicking here now.

About TRACON Pharmaceuticals Stock (NASDAQ:TCON)

TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel targeted therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of refractory soft tissue sarcoma; and YH001, an investigational humanized cytotoxic T-lymphocyte-associated protein 4 IgG1 monoclonal antibody that is in Phase I clinical trial for the treatment of various cancer indications. The company's clinical stage products also include TRC102, a small molecule that is in Phase II clinical trial for the treatment of mesothelioma, and in Phase I clinical trial to treat solid tumors and lymphomas, lung cancer, and glioblastoma; and TJ004309, a CD73 antibody that is in Phase I clinical development for the treatment of solid tumors. In addition, it is developing bispecific antibodies, which are in preclinical stage. It has collaboration and license agreements with 3D Medicines Co., Ltd. and Jiangsu Alphamab Biopharmaceuticals Co., Ltd. for the development of envafolimab; I-Mab Biopharma for the development of CD73 antibody TJ004309 and bispecific antibodies; and cooperative research and development agreement with National Cancer Institute. The company was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005. TRACON Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in San Diego, California.

TCON Stock Price History

30 days | 90 days | 365 days | Advanced Chart

TCON Stock News Headlines

April 16, 2024 | americanbankingnews.com

TRACON Pharmaceuticals (NASDAQ:TCON) Research Coverage Started at StockNews.com

April 10, 2024 | markets.businessinsider.com

Buy Rating Reaffirmed for TRACON Pharmaceuticals Post-Reverse Split and Envafolimab Valuation Update

April 18, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

April 10, 2024 | uk.investing.com

TRACON announces 1-for-20 reverse stock split

April 10, 2024 | investorplace.com

Wall Street Favorites: 3 Penny Stocks With Strong Buy Ratings for April 2024

April 8, 2024 | marketwatch.com

Shares of Tracon Pharmaceuticals Tumble 22% on Reverse Split

April 8, 2024 | finanznachrichten.de

TRACON Pharmaceuticals, Inc.: TRACON Pharmaceuticals Announces Reverse Stock Split

April 8, 2024 | globenewswire.com

TRACON Pharmaceuticals Announces Reverse Stock Split

April 18, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

April 8, 2024 | americanbankingnews.com

TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) Expected to Post FY2025 Earnings of ($0.27) Per Share

April 8, 2024 | americanbankingnews.com

TRACON Pharmaceuticals (NASDAQ:TCON) Coverage Initiated at StockNews.com

April 4, 2024 | markets.businessinsider.com

Buy Rating Affirmed for TRACON Pharmaceuticals Amid Promising Envafolimab Trial Outlook

April 3, 2024 | msn.com

Tracon Pharma drops after pivotal data for cancer drug

April 3, 2024 | finance.yahoo.com

TRACON Pharmaceuticals Provides Update on Ongoing ENVASARC Phase 2 Pivotal Trial Following Independent Data Monitoring Committee Recommendation to Continue the Trial as Planned

March 13, 2024 | markets.businessinsider.com

JonesTrading Reaffirms Their Hold Rating on TRACON Pharmaceuticals (TCON)

March 8, 2024 | markets.businessinsider.com

Buy Rating for TRACON Pharmaceuticals on Strong Financials and Promising Clinical Trials

March 7, 2024 | finanznachrichten.de

TRACON Pharmaceuticals, Inc.: TRACON Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update

March 7, 2024 | seekingalpha.com

TRACON Pharmaceuticals, Inc. (TCON) Q4 2023 Earnings Call Transcript

March 7, 2024 | finance.yahoo.com

TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) Q4 2023 Earnings Call Transcript

March 5, 2024 | globenewswire.com

TRACON Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update

March 4, 2024 | msn.com

Tracon Q4 2023 Earnings Preview

March 4, 2024 | benzinga.com

A Preview Of TRACON Pharma's Earnings

February 28, 2024 | globenewswire.com

TRACON to Report Fourth Quarter and Year-End 2023 Financial Results and Provide Corporate Update on March 5, 2024

February 13, 2024 | finance.yahoo.com

TRACON Pharmaceuticals, Inc. (TCON)

December 23, 2023 | benzinga.com

TRACON Pharma Stock (NASDAQ:TCON), Guidance and Forecast

December 21, 2023 | markets.businessinsider.com

Buy Rating for TRACON Pharmaceuticals on Envafolimab’s Promising Trial Outcomes and Strong Market Potential

November 25, 2023 | seekingalpha.com

TCON TRACON Pharmaceuticals, Inc.

See More Headlines

Receive TCON Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for TRACON Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/05/2024
Today: 4/18/2024
Next Earnings (Estimated): 5/08/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Current Symbol: NASDAQ:TCON
CUSIP: N/A
CIK: 1394319
Web: www.traconpharma.com
Phone: (858) 550-0780
Fax: 858-550-0786
Employees: 17
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $60.00
High Stock Price Target: $60.00
Low Stock Price Target: $60.00
Potential Upside/Downside: +2,743.6%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.67
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($5.20)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-3,590,000.00
Net Margins: N/A
Pretax Margin: -29.79%
Return on Equity: -10.25%
Return on Assets: 7.86%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.89
Quick Ratio: 0.89

Sales & Book Value

Annual Sales: $12.05 million
Price / Sales: 0.40
Cash Flow: $2.11 per share
Price / Cash Flow: 1.00
Book Value: ($0.37) per share
Price / Book: -5.70

Miscellaneous

Outstanding Shares: 2,280,000
Free Float: 2,155,000
Market Cap: $4.81 million
Optionable: No Data
Beta: 0.95

Elon Musk's Next Move

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

Dr. Charles P. Theuer M.D. (Age 60)
Ph.D., Chairman, CEO & President
Comp: $646.6k
Mr. Scott B. Brown CPA (Age 43)
M.S., Chief Financial Officer
Comp: $403.1k
Dr. James L. Freddo (Age 69)
Chief Medical Officer
Mr. Ya Huang
Executive Director of Statistical Programming

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

TCON Stock Analysis - Frequently Asked Questions

Should I buy or sell TRACON Pharmaceuticals stock right now?: 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TRACON Pharmaceuticals in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" TCON shares.
View TCON analyst ratings or view top-rated stocks.
What is TRACON Pharmaceuticals' stock price target for 2024?: 3 analysts have issued 12-month price targets for TRACON Pharmaceuticals' shares. Their TCON share price targets range from $60.00 to $60.00. On average, they expect the company's share price to reach $60.00 in the next year. This suggests a possible upside of 2,743.6% from the stock's current price.
View analysts price targets for TCON or view top-rated stocks among Wall Street analysts.
How have TCON shares performed in 2024?: TRACON Pharmaceuticals' stock was trading at $3.5020 at the start of the year. Since then, TCON shares have decreased by 39.7% and is now trading at $2.11.
View the best growth stocks for 2024 here.
Are investors shorting TRACON Pharmaceuticals?: TRACON Pharmaceuticals saw a drop in short interest during the month of March. As of March 31st, there was short interest totaling 744,900 shares, a drop of 60.8% from the March 15th total of 1,900,000 shares. Based on an average daily trading volume, of 3,400,000 shares, the short-interest ratio is presently 0.2 days.
View TRACON Pharmaceuticals' Short Interest.
When is TRACON Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our TCON earnings forecast.
How were TRACON Pharmaceuticals' earnings last quarter?: TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) announced its quarterly earnings data on Tuesday, March, 5th. The biopharmaceutical company reported $0.20 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.60) by $0.80. The biopharmaceutical company had revenue of $3.41 million for the quarter, compared to analysts' expectations of $3 million.

When did TRACON Pharmaceuticals' stock split?: TRACON Pharmaceuticals's stock reverse split on the morning of Wednesday, April 10th 2024. The 1-20 reverse split was announced on Wednesday, April 10th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, April 10th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.
What other stocks do shareholders of TRACON Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other TRACON Pharmaceuticals investors own include NVIDIA (NVDA), OPKO Health (OPK), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Verastem (VSTM), Inovio Pharmaceuticals (INO), T2 Biosystems (TTOO), AVEO Pharmaceuticals (AVEO), Corbus Pharmaceuticals (CRBP) and Onconova Therapeutics (ONTX).
When did TRACON Pharmaceuticals IPO?: TRACON Pharmaceuticals (TCON) raised $47 million in an IPO on Friday, January 30th 2015. The company issued 3,600,000 shares at $12.00-$14.00 per share. Wells Fargo Securities and Stifel served as the underwriters for the IPO and Needham & Company and Oppenheimer were co-managers.
How do I buy shares of TRACON Pharmaceuticals?: Shares of TCON stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:TCON) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial